Central Venous Access Device Removal in Cancer Patients

Status Completed

Clinical Trial Summary

Background:

Central venous catheters are frequently used during cancer treatment with the aim of venepreservation. It can facilitate venous access for the safe administration of irritating or vesicant intravenous cancer medications and / or other fluids, to collect blood samples or to ensure accurate venous access for contrast during medical imaging. In addition, this means more comfort for the patient who needs to be punctured less peripherally. However, central venous catheters can also be a source of bloodstream infections and other complications, leading to increased morbidity and hospital costs (1). In our hospital, there is a general practice that if an infection of the device is suspected, the central venous catheter should be removed if antibiotics do not seem or prove to be effective.

The objective of this trial is to assess the frequency of implanted port catheter-removal in cancer patients due to suspected infection of the device in a particular oncology center over a time period of seven years. Furthermore, evidence for real device infections (per/post-surgery) and the potential contribution of different (institution-specific) risk factors on device infection will be explored. There will be focused on implanted port catheters only, as this is the main used central venous access device within the oncological population.

Trial objectives:

The primary aim of this retrospective descriptive trial is to evaluate the frequency of implanted port catheter-removal in cancer patients due to suspected infection of the device, over a time period of seven years.

The secondary aim is to examine whether the device infection could be confirmed during or after removal of the device.

At last, the tertiary aim is to verify whether certain variables can be denoted as potential risk factors for central venous access infection. Selection of those variables of interest will be based on a thorough review of the literature and discussion with the responsible healthcare professionals.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03855969
Study type	Observational
Source	General Hospital Groeninge
Contact
Status	Completed
Phase
Start date	March 1, 2019
Completion date	December 30, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01439152` - Phase I Study to Determine the Maximum Tolerable Dose of BAY94-9343 in Patients With Advanced Solid Tumors.	Phase 1
Recruiting	`NCT05615246` - Exactech Humeral Reconstruction Prosthesis of Shoulder Arthroplasty PMCF (HRP)
Active, not recruiting	`NCT06015009` - Symptom Management App for Children at the Early Stage of Cancer Survivorship and Their Caregivers	N/A
Active, not recruiting	`NCT03298100` - Risk Scoring Model for Endometrial Cancer
Recruiting	`NCT05055609` - Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors	Phase 1
Not yet recruiting	`NCT04324320` - Psychological Distress in Outpatient Oncological Rehabilitation
Completed	`NCT00588289` - Long Term Follow-Up of Patients on Children's Cancer Group Protocols- (CCG-LTF1) FOLLOW-UP DATA	N/A
Recruiting	`NCT06222801` - The 1st Tumor CytokinoTherapy Database (TCTD-1)
Recruiting	`NCT03831633` - Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients	Phase 4
Completed	`NCT04914702` - Feasibility and Comparison of Continuously Monitored Vital Signs in Pediatric Patients With Cancer.
Recruiting	`NCT05198570` - Pharmacokinetics of Intravenous Acyclovir in Oncologic Paediatric Patients
Recruiting	`NCT05712174` - A Study of [18]F-PSMA-1007 in Patients With Known or Suspected Metastatic Prostate Cancer	Phase 2
Recruiting	`NCT03832062` - Value of Analysing Under-utilised Leftover Tissue (VauLT)
Completed	`NCT03988777` - Magnetic Seed Localisation for Nonpalpable Breast Lesions
Recruiting	`NCT06031233` - Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie	Phase 4
Enrolling by invitation	`NCT04019119` - Digital Intervention for the Modification of Lifestyles (iGame)	N/A
Not yet recruiting	`NCT05926362` - Capillary-Venous Paired Data Collection
Recruiting	`NCT05686213` - ExeNTrO: Exercise During Neoadjuvant Chemoradiation Treatment to Improve Rectal and Esophageal Cancer Outcome - Pilot Trial	Phase 2
Recruiting	`NCT05510856` - Comparative Clinical Study Evaluating the Possible Efficacy of Duloxetine, Gabapentin and Lacosamide on Oxaliplatin-Induced Peripheral Neuropathy in Cancer Patients	Phase 4
Completed	`NCT04933604` - LPN in Patients With High-complex Renal Tumors

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.